Eone Diagnomics Genome CenterEDGC
245620 · KOSDAQ · ₩245620 · EDGC
- Market cap
- ₩167B
- Enterprise value
- ₩156B
- P/E
- 3.8×
- P/B
- 7.2×
- Dividend yield
- 0.0%
- ROE
- 189.4%
- Net margin
- 693.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range0.0% from the high
₩741Today: ₩741 – ₩741₩741
Returns
- 1W0.0%
- 1M0.0%
- 3M0.0%
- 6M0.0%
- YTD0.0%
- 1Y0.0%
- Volume today
- —
- Traded today
- —
- Listed shares
- 225,531,114
- EPS (12 months)
- ₩194
- Earnings yield 26.2%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Eone Diagnomics Genome Center stock overview
Eone Diagnomics Genome Center (EDGC, KRX: 245620) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean global bio genome big-data firm, founded in 2013 as a joint venture between Korean clinical diagnostics lab E-Won Medical Foundation and US-based Diagnomics, Inc. Its shares closed at ₩741 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩167B.
Key facts
- Market cap
- ₩167B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- The company is a Korean global bio genome big-data firm, founded in 2013 as a joint venture between Korean clinical diagnostics lab E-Won Medical Foundation and US-based Diagnomics, Inc.
Quick answers about Eone Diagnomics Genome Center
- What does Eone Diagnomics Genome Center do?
- The company is a Korean global bio genome big-data firm, founded in 2013 as a joint venture between Korean clinical diagnostics lab E-Won Medical Foundation and US-based Diagnomics, Inc. Its main offerings are genome analysis services, including the YouWho ancestry analysis service, the NICE non-invasive prenatal test, and liquid biopsy cancer testing (OncoCatch), sold to individuals and to hospitals and clinics. It also sells health functional foods made at a Canadian facility it acquired in Burnaby, British Columbia, and is developing genome-based drug discovery.
- What is the market cap of Eone Diagnomics Genome Center?
- The market capitalisation of Eone Diagnomics Genome Center was ₩167B at the close on Oct 27, 2026.
- Who are the largest shareholders of Eone Diagnomics Genome Center?
- According to the latest official filings, the largest reported holders are Eirom (48.77%, as of May 8, 2026); AIT Story (24.39%, as of May 7, 2026); Bitgwa Electronics (9.21%, as of Jul 10, 2026).
- When is the next earnings report from Eone Diagnomics Genome Center?
- Korean companies rarely announce results dates in advance. Based on when Eone Diagnomics Genome Center filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company is a Korean global bio genome big-data firm, founded in 2013 as a joint venture between Korean clinical diagnostics lab E-Won Medical Foundation and US-based Diagnomics, Inc. Its main offerings are genome analysis services, including the YouWho ancestry analysis service, the NICE non-invasive prenatal test, and liquid biopsy cancer testing (OncoCatch), sold to individuals and to hospitals and clinics. It also sells health functional foods made at a Canadian facility it acquired in Burnaby, British Columbia, and is developing genome-based drug discovery.
Written by AI from the company's latest annual report.
- Korean name
- EDGC
- Sector
- Biotech & Pharma
- CEO
- 마민철, 김봉조 (각자대표)
- Founded
- May 2013
- Listed
- Jun 2018
- Listed shares
- 225,531,114
- Fiscal year ends
- Month 12
- Website
- www.edgc.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Change of CEOAug 28, 2026
- Application for Termination of Rehabilitation ProceedingsAug 26, 2026
- [Correction] Approval of Rehabilitation PlanAug 26, 2026
- Other Market Notice (No Market Measures Yet Taken Regarding Partial Lifting of Investment Caution Designation)Aug 14, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: Eone Diagnomics Genome Center / EDGC / 245620 / KRX:245620
Source: KRX statistical information